DARIUS MCGEE: Open Payments
NPI 1619004744 · LAUREL, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$807 in 42 payments from 8 companies in 2025. Trend: 2023 $572 · 2024 $485 · 2025 $807
Food & beverage: $807
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $318 |
| ABBVIE INC. | 16 | $248 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $99 |
| Novo Nordisk Inc | 2 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $21 |
| PFIZER INC. | 1 | $17 |
| Abbott Laboratories | 1 | $16 |
Products named: VRAYLAR, AIRSUPRA, BREZTRI, XIFAXAN, QULIPTA, Ozempic, CAPLYTA, Kerendia.
Industry payments across MS — which companies pay providers there.
